drugset / Trial / NCT03264651

Enobosarm and Anastrozole in Pre-menopausal Women With High Mammographic Breast Density

NCT03264651

Phase 1 Completed 9 enrolled Havah Therapeutics Pty Ltd GTx · collab
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the impact of a selective androgen receptor modulator combined with an aromatase inhibitor in reducing high mammographic breast density.

Timeline

Start
2017-02-01
Primary completion
2018-03-21
Completion
2018-03-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Anastrozole Other / unclassified 1 mg Oral
Subject Enobosarm Small molecule 9 mg Oral

Indications